251 related articles for article (PubMed ID: 9155167)
21. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
22. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
Cutrupi S; Reineri S; Panetto A; Grosso E; Caizzi L; Ricci L; Friard O; Agati S; Scatolini M; Chiorino G; Lykkesfeldt AE; De Bortoli M
Oncogene; 2012 Oct; 31(40):4353-61. PubMed ID: 22249258
[TBL] [Abstract][Full Text] [Related]
23. Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.
Naundorf H; Jost-Reuhl B; Becker M; Reuhl T; Neumann C; Fichtner I
Breast Cancer Res Treat; 2000 Mar; 60(1):81-92. PubMed ID: 10845812
[TBL] [Abstract][Full Text] [Related]
24. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of estrogen receptor, antiestrogen binding sites and calmodulin for antiestrogen resistance of two clones derived from the MCF-7 breast cancer cell line.
Borras M; Jin L; Bouhoute A; Legros N; Leclercq G
Biochem Pharmacol; 1994 Nov; 48(11):2015-24. PubMed ID: 7802690
[TBL] [Abstract][Full Text] [Related]
26. A molecular strategy to control tamoxifen resistant breast cancer.
Jiang SY; Jordan VC
Cancer Surv; 1992; 14():55-70. PubMed ID: 1423331
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen resistance in breast cancer: elucidating mechanisms.
Dorssers LC; Van der Flier S; Brinkman A; van Agthoven T; Veldscholte J; Berns EM; Klijn JG; Beex LV; Foekens JA
Drugs; 2001; 61(12):1721-33. PubMed ID: 11693462
[TBL] [Abstract][Full Text] [Related]
28. Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.
De Oliveira Andrade F; Yu W; Zhang X; Carney E; Hu R; Clarke R; FitzGerald K; Hilakivi-Clarke L
Endocr Relat Cancer; 2019 Mar; 26(3):339-353. PubMed ID: 30640711
[TBL] [Abstract][Full Text] [Related]
29. Comparison of tamoxifen ligands on estrogen receptor interaction with estrogen response elements.
Klinge CM; Studinski-Jones AL; Kulakosky PC; Bambara RA; Hilf R
Mol Cell Endocrinol; 1998 Aug; 143(1-2):79-90. PubMed ID: 9806352
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor.
Li Y; Cook KL; Yu W; Jin L; Bouker KB; Clarke R; Hilakivi-Clarke L
Nutrients; 2021 May; 13(5):. PubMed ID: 34069442
[TBL] [Abstract][Full Text] [Related]
31. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.
Schoenlein PV; Periyasamy-Thandavan S; Samaddar JS; Jackson WH; Barrett JT
Autophagy; 2009 Apr; 5(3):400-3. PubMed ID: 19221464
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review).
Viedma-Rodríguez R; Baiza-Gutman L; Salamanca-Gómez F; Diaz-Zaragoza M; Martínez-Hernández G; Ruiz Esparza-Garrido R; Velázquez-Flores MA; Arenas-Aranda D
Oncol Rep; 2014 Jul; 32(1):3-15. PubMed ID: 24841429
[TBL] [Abstract][Full Text] [Related]
33. Studies on mechanisms of estrogen and antiestrogen action in human breast cancer.
Horwitz KB; McGuire WL
Recent Results Cancer Res; 1980; 71():45-58. PubMed ID: 6988916
[TBL] [Abstract][Full Text] [Related]
34. Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications.
Johnston SR
Anticancer Drugs; 1997 Nov; 8(10):911-30. PubMed ID: 9436634
[TBL] [Abstract][Full Text] [Related]
35. Antiestrogen resistance in ER positive breast cancer cells.
Paik S; Hartmann DP; Dickson RB; Lippman ME
Breast Cancer Res Treat; 1994; 31(2-3):301-7. PubMed ID: 7881107
[TBL] [Abstract][Full Text] [Related]
36. The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance.
Suba Z
Drug Des Devel Ther; 2015; 9():4341-53. PubMed ID: 26273195
[TBL] [Abstract][Full Text] [Related]
37. Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?
Bhattacharya P; Abderrahman B; Jordan VC
Expert Rev Anticancer Ther; 2017 Apr; 17(4):297-310. PubMed ID: 28281842
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
Mittal R; Chaudhry N; Pathania S; Mukherjee TK
Curr Pharm Biotechnol; 2014; 15(12):1141-57. PubMed ID: 25429654
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen Resistance: Emerging Molecular Targets.
Rondón-Lagos M; Villegas VE; Rangel N; Sánchez MC; Zaphiropoulos PG
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548161
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of tamoxifen resistance.
Osborne CK; Fuqua SA
Breast Cancer Res Treat; 1994; 32(1):49-55. PubMed ID: 7819585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
